Introduction: The Paragraph IV Filing as Corporate Weapon A Paragraph IV certification is the most powerful offensive instrument in the […]

1. The Core Tension: Why Launch Pricing Breaks Finance Departments Pharmaceutical launch pricing is the only commercial decision in modern

The generic drug industry runs on a paradox. Generics fill more than 90% of all U.S. prescriptions yet account for

Branded drugs generating $356 billion in worldwide sales face patent expiration between 2023 and 2028. Every one of those assets

1. Market Scale and Growth Trajectory Sizing the Opportunity The global generic drug market sat between $488 billion and $491

Key Takeaways Section 1: The Patent Cliff Reframed: A Market Transformation, Not a Disaster 1.1 The Standard Narrative Gets It

The Drug Price Competition and Patent Term Restoration Act of 1984 — the Hatch-Waxman Act — is the single piece

Generic and biosimilar drugs saved the U.S. healthcare system $445 billion in 2023 alone, accumulating to over $2.9 trillion across

Section 1: The 505(b)(2) Value Proposition — Pricing Incremental Innovation 1.1 Why the Pathway Exists and What It Actually Does